Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880760 | 0.84 | PLCG1 (0.43) | ALDH1A1KDM4ESMN1; SMN2PLCG1MMP2 | |
| SCHEMBL22551922 | 0.84 | PLCG1 (0.43) | ALDH1A1KDM4ESMN1; SMN2PLCG1MMP2 | |
| SCHEMBL22552118 | 0.83 | HTR7 (0.49) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL3470698 | 0.80 | SMN1; SMN2 (0.49) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL4282591 | 0.76 | L3MBTL1 (0.47) | ALDH1A1KDM4ESMN1; SMN2PLCG1L3MBTL1 | |
| SCHEMBL22366589 | 0.75 | SLC22A12 (0.38) | ALDH1A1MMP2 | |
| SCHEMBL22552075 | 0.75 | PDE5A (0.43) | ALDH1A1KDM4EPLCG1 | |
| SCHEMBL19384152 | 0.75 | KDM4E (0.49) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL22551784 | 0.74 | USP8 (0.43) | ALDH1A1KDM4ESMN1; SMN2PLCG1LMNA | |
| SCHEMBL11498598 | 0.73 | PDE5A (0.45) | ALDH1A1KDM4EPLCG1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-10898481-B2 | Pyrazine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-26 | — | — | US | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10898481-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | ALDH1A1 1105/4885KDM4E 4220/4885SMN1; SMN2 4427/4885 |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | ALDH1A1 1105/4885KDM4E 4220/4885SMN1; SMN2 4427/4885 |
| US-11571420-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | ALDH1A1 1105/4885KDM4E 4220/4885SMN1; SMN2 4427/4885 |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | ALDH1A1 1105/4885KDM4E 4220/4885SMN1; SMN2 4427/4885 |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | ALDH1A1 1105/4885KDM4E 4220/4885SMN1; SMN2 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.